| |
|
|
|
|
|
|
|
|
|
 |
Argument 227 The following appeared in the business section of a newspaper. "Given that the number of people in our country with some form of arthritis is expected to rise from 40 million to 60 million over the next twenty years, pharmaceutical companies that produce drugs for the treatment of arthritis should be very profitable. Many analysts believe that in ten years Becton Pharmaceuticals, which makes Xenon, the best-selling drug treatment for arthritis, will be the most profitable pharmaceutical company. But the patent on Xenon expires in three years, and other companies will then be able to produce a cheaper version of the drug. Thus, it is more likely that in ten years the most profitable pharmaceutical company will be Perkins Pharmaceuticals, maker of a new drug called Xylan, which clinical studies show is preferred over Xenon by seven out of ten patients suffering from the most extreme cases of arthritis." ------------------------------ |
Home Privacy Policy Copyright And Terms Registration Recommend To A Friend Contact Us
Copyright ©2004 Grois. All rights reserved.
*Test names and other trademarks are the property of the respective trademark holders.
None of the trademark holders are affiliated with Grois or this web site.